Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
Open Access
- 9 January 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (1), 54
- https://doi.org/10.3390/pharmaceutics12010054
Abstract
Antimicrobial treatment in critically ill patients remains challenging. The aim of this study was to develop a population pharmacokinetic model for linezolid in critically ill patients and to evaluate the adequacy of current dosing recommendation (600 mg/12 h). Forty inpatients were included, 23 of whom were subjected to continuous renal replacement therapies (CRRT). Blood and effluent samples were drawn after linezolid administration at defined time points, and linezolid levels were measured. A population pharmacokinetic model was developed, using NONMEM 7.3. The percentage of patients that achieved the pharmacokinetic/pharmacodynamic (PK/PD) targets was calculated (AUC24/MIC > 80 and 100% T>MIC). A two-compartment model best described the pharmacokinetics of linezolid. Elimination was conditioned by the creatinine clearance and by the extra-corporeal clearance if the patient was subjected to CRRT. For most patients, the standard dose of linezolid did not cover infections caused by pathogens with MIC ≥ 2 mg/L. Continuous infusion may be an alternative, especially when renal function is preserved.Funding Information
- University of the Basque Country UPV/EHU (PPG17/65, GIU17/32)
- Pfizer (012 ASPIRE EUMRSA)
This publication has 31 references indexed in Scilit:
- Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysisJournal of Antimicrobial Chemotherapy, 2013
- Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapyCritical Care Medicine, 2012
- How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamicsInternational Journal of Antimicrobial Agents, 2012
- Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric AnalysisAntimicrobial Agents and Chemotherapy, 2010
- Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patientsJournal of Antimicrobial Chemotherapy, 2008
- Epidemiología del fracaso renal agudo en las UCI españolas. Estudio prospectivo multicéntrico FRAMIMedicina Intensiva (English Edition), 2006
- Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement TherapyClinical Infectious Diseases, 2005
- Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltrationJournal of Antimicrobial Chemotherapy, 2005
- Pharmacokinetics of Linezolid in Subjects with Renal DysfunctionAntimicrobial Agents and Chemotherapy, 2003
- Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infectionsJournal of Antimicrobial Chemotherapy, 2003